68Ga-DOTATATE Neuroblastoma Imaging Pilot

Summary

Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.

Timeline

Start

2021-12-06

Primary completion

2027-12-15

Completion

2028-09-30

Drugs

Indications